Replies to post #7130 on NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

This was quite a good point:

Also, The DCVax-L Phase III trial has an unusual element in that 33 patients were enrolled and treated 2006-2008, so there is data from that subset giving a long term view into results.

That is a good % of those treated offering a long view look. Should bode well with the FDA I'm sure. Hmm..